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A characteristic of many positive-strand RNA viruses is that, whilst replication of the viral genome is
dependent on the expression of the majority of non-structural proteins in cis, virus particle formation
can occur when most or all of the structural proteins are co-expressed in trans. Making use of a
recently identified hepatitis C virus (HCV) isolate (JFH1) that can be propagated in tissue culture,
this study sought to establish whether this is also the case for hepaciviruses. Stable cell lines
containing one of two bicistronic replicons derived from the JFH1 isolate were generated that
expressed non-structural proteins NS3–5B or NS2–5B. Release and transmission of these
replicons to naı¨ve Huh7 cells could then be demonstrated when baculovirus transduction was used
to express the HCV proteins absent from the subgenomic replicons. Transmission could be blocked
by a neutralizing antibody targeted at the E2 envelope protein, consistent with this phenomenon
occurring via trans-encapsidation of replicon RNA into virus-like particles. Transmission was also
dependent on expression of NS2, which was most effective at promoting virus particle formation
when expressed in cis on the replicon RNA compared with in trans via baculovirus delivery. Density
gradient analysis of the particles revealed the presence of a broad infectious peak between 1.06
and 1.11 g ml”1, comparable to that seen when propagating full-length virus in tissue culture. In
summary, the trans-encapsidation system described offers a complementary and safer approach to
study HCV particle formation and transmission in tissue culture.
INTRODUCTION
Current estimates are that 170 million individuals are
persistently infected with hepatitis C virus (HCV)
throughout the world. Although initially many HCV-
positive individuals will exhibit few clinical signs of
infection, a significant health burden is associated with
long-term chronic virus infection, with recent estimates
suggesting that there is a three-fold increased risk of death
above background levels, primarily due to liver disease,
suicide and possibly cardiovascular complications
(Guiltinan et al., 2008). Therapeutic intervention is
available, but therapies are poorly tolerated and only
partially effective (Deutsch & Hadziyannis, 2008).
Furthermore, a vaccine for HCV is not available, and
whilst it may be possible to develop one, our current
understanding of how the immune system eliminates this
virus suggests that such a vaccine would need to stimulate a
cell-mediated immune response against a broad range of
major histocompatibility complex class I and II epitopes
(Day et al., 2003; Lauer et al., 2004). Therefore, there is a
need for further research into various aspects of the HCV
life cycle, both in terms of identification of novel targets for
therapeutic intervention and to establish how the virus is
able to circumvent both adaptive and innate immunity.
HCV is a positive-strand, enveloped RNA virus belonging
to the family Flaviviridae and possesses a 9.6 kb genome
containing a single open reading frame (ORF) flanked by
59 and 39 untranslated regions (UTRs). Translation of this
ORF is directed by an internal ribosome entry site (IRES)
found within the 59 UTR, resulting in the production of a
single polypeptide that is cleaved by host and viral
proteases into structural and non-structural proteins,
respectively (reviewed by Suzuki et al., 2007).
Historically, HCV research has been restricted by the
inability to cultivate the virus effectively in vitro. However,
two major advances have helped to alleviate this problem.
The first of these was the development of the HCV
replicon, a bicistronic HCV subgenomic RNA construct
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lacking structural proteins, but expressing neomycin
phosphotransferase to allow selection of cells capable of
maintaining the replicon in culture (Lohmann et al., 1999).
This enabled identification of mutations in the HCV
genome that promoted replication of HCV transcripts in
tissue culture cells (Blight et al., 2000; Krieger et al., 2001;
Lohmann et al., 2001). However, these same mutations did
not facilitate production of infectious particles
(Pietschmann et al., 2002) and were shown to attenuate
virus infectivity in vivo (Bukh et al., 2002). More recently,
an HCV genotype 2a isolate (JFH1) has been identified,
which is infectious in vivo but is also capable of replicating
and producing virus particles in cell culture (HCVcc)
without the need for culture adaptation (Lindenbach et al.,
2005; Wakita et al., 2005; Zhong et al., 2005). Importantly,
replicons derived from JFH1 demonstrate robust replica-
tion in tissue culture without the requirement for culture-
adaptive mutations (Date et al., 2004; Kato et al., 2003).
We speculated that it should be possible to develop a trans-
encapsidation system for HCV using a replicon-based
system, given that it has been successfully reported for
other members of the family Flaviviridae (Gehrke et al.,
2003; Jones et al., 2005; Khromykh et al., 1998), but that it
would require the use of JFH1 constructs to avoid
utilization of culture-adapted mutations. Our findings are
consistent with this hypothesis and demonstrate that trans-
encapsidation of the HCV genome can be achieved under
laboratory conditions. Viral trans-encapsidation systems
can be useful vaccine-delivery systems (Anraku et al., 2002;
Pushko et al., 1997; Zhou et al., 1994) and, with further
development, HCV trans-encapsidation systems may
provide novel ways of generating protective immune
responses against infectious virus.
METHODS
Cells and viruses. Huh7 cells (a gift from Professor R.
Bartenschlager, Department of Molecular Virology, University of
Heidelberg, Germany) were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10 % fetal calf serum (FCS),
2 mM glutamine, 16 non-essential amino acids, 25 mM HEPES,
50 U penicillin (Invitrogen) and 50 mg streptomycin ml21
(Invitrogen). Sf9 cells were maintained in TC100 with 10 % FCS,
50 U penicillin and 50 mg streptomycin ml21 and used to isolate,
amplify and titrate baculovirus clones by using standard procedures.
Recombinant baculovirus was generated by using the Bac-to-Bac
system (Invitrogen) according to the manufacturer’s recommenda-
tions. Concentrated baculovirus stocks were obtained by clarification
of the virus supernatant using a 0.45 mm filter and centrifugation
(26 000 r.p.m. in a Beckman SS28 rotor for 1 h at 4 uC), and were
resuspended in PBS. For transduction experiments, cells containing
replicons were seeded 20–24 h in advance at a cell density of 2.06104
cells cm22. Unless otherwise stated, cells were then incubated with
46107 p.f.u. baculovirus ml21 for 4 h and allowed to recover for
between 24 and 72 h before recovering the supernatant, which was
filtered through a 0.45 mm syringe filter and assessed for the presence
of trans-encapsidated replicon.
DNA constructs. pSGR-JFH1(GND), pSGR-JFH1 [referred to as
pSGR-JFH1(NS3–5B) for the purposes of this study] and pJFH1 were
gifts from Professor T. Wakita (National Institute of Infectious
Diseases, Tokyo, Japan). To generate pSGR-JFH1(NS2–5B), the
KpnI–NsiI fragment from pSGR-JFH1(NS3–5B) was first excised
and replaced with the KpnI–NsiI fragment from pJFH1 to produce a
construct lacking a portion of both the encephalomyocarditis virus
(EMCV) IRES and NS2. The resulting plasmid was then linearized
with KpnI to allow insertion of the remaining EMCV IRES/NS2
sequence, the DNA for which was generated by a two-step PCR. The
first round of this PCR utilized primer pairs EMCV(fwd) (59-
GCGTATTCAACAAGGGGCTGAAG-39) and JFH_EMCV(revfus)
(59-GTGCGTCATACATGGTATTATCGTGTTTTTCAAAGG-39), and
JFH_NS2(fwdfus) (59-GATAATACCATGTATGACGCACCTGTGCA-
CGG-39) and JFH_NS2(rev) (59-CCTGCATGGGTGGTACCCACTC-
39), respectively, and the second round used primers EMCV(fwd) and
JFH_NS2(rev). In order to generate the baculovirus constructs
expressing JFH1 structural proteins, it was first necessary to create a
Bac-to-Bac transfer vector for expression of genes under the control of
a hybrid constitutive immediate-early human cytomegalovirus enhan-
cer/chicken b-actin (CA) promoter. To do this, the SphI (polished with
PfuI)–HindIII fragment from pBACMAM-2 (Novagen) was transferred
to the pFB(XbaI–HindIII) vector (McCormick et al., 2006) cut with
XbaI (polished with PfuI) and HindIII, generating pFBM. DNAs
encoding the regions core–P7 and core–NS2 from pJFH1 were
amplified by PCR using primer pairs CORE(JFH_RI) (59-
GAGAGAGAATTCGCCACCATGAGCACAAATCCTAAACC-39) and
P7(JFH_RI) (59-GAGAGAGAATTCTTAGGCATAAGCCTGCCGGG-
GCAG-39), and CORE(JFH_RI) and NS2(JFHRIrev) (59-GAGAGA-
GAATTCTTAAAGGAGCTTCCACCCCTTGGAG-39), respectively,
and cloned into pFBM by using EcoRI to generate pFBM(JFH1)C–P7
and pFBM(JFH1)C–NS2. To produce pFBM-derived structural protein
expression constructs containing the F172C and P173S mutations at
the COOH end of the core, DNAs encoding the core region and the E1–
P7 region were amplified by using primer pairs CORE(JFH_RI) and
CORESPMOD (59-CAGGGCCAGCAAGAAGATAGAAAAGCTGCA-
GCCGGGTAGGTTCCCTGTTGC-39), and SPE1JFH(fwd) (59-GA-
GAGAGAATTCGCCACCATGGGCTGCAGCTTTTCTATCTTCTTG-
CTGG-39) and P7(JFH_RI). The PCR product encoding the E1–P7
region was cloned into pFBM by using EcoRI, generating
pFBM(JFH1)E1–P7*, or both PCR products were digested with
PstI+EcoRI and cloned into EcoRI-cut pFBM as a three-way ligation,
generating pFBM(JFH1)C–P7*. All FBM baculovirus constructs were
derived from the respective pFBM vectors described above. The
sequences of vectors are available on request.
Colony-forming assays. To produce RNA for transfection into cells,
5 mg each replicon-containing DNA construct was linearized with XbaI,
polished with mung bean nuclease (NEB) and used as a template in a
50 ml T7 RNA polymerase reaction following the manufacturer’s
recommendations (NEB), but performed at 30 uC for 2 h using 2 mM
each rNTP. RQ1 DNase (Promega) was then used to remove the DNA
template, and the transcripts were purified by using an RNA Clean-up
kit 25 (Zymo Research). The integrity of the transcripts was confirmed
by MOPS/formaldehyde gel electrophoresis before electroporating 1 mg
each transcript into Huh7 cells and performing a colony-forming assay.
Details of this are essentially as described previously (McCormick et al.,
2004) except that, during the 2-week selection period, the concentra-
tion of G418 (Melford Laboratories) was reduced from 750 mg ml21
(first feed) to 500 mg ml21 (second feed) and finally to 250 mg ml21
(third and fourth feeds).
To detect trans-encapsidated replicons, naı¨ve Huh7 cells were seeded
at 26104 cells cm22 in six-well dishes and allowed to recover
overnight. The next day, the medium was replaced with 2 ml neat
supernatant from trans-encapsidation experiments or gradient
fractions (0.5 ml diluted with 1.5 ml medium) and the cells were
left for a further 24 h before initiating selection with G418. The
concentration and timing of the G418 selection schedule was the same
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as that described above. Antibodies used in neutralization experi-
ments were the anti-E2 monoclonal antibody (mAb) AP33 (Clayton
et al., 2002) and the anti-herpes simplex virus VP5 mAb DM165 (a
gift from Dr F. Rixon, MRC Virology Unit, Glasgow, UK).
Equilibrium gradients. The low concentration of infectious particles
containing replicon RNA in the supernatant necessitated the adoption
of a modified protocol to assess particle density, similar to that
described by others (Lindenbach et al., 2006; Stone, 1974). Briefly, a
6.3 ml solution of a 2 : 1 mix of iodixanol : trans-encapsidated
supernatant was placed in a 14695 mm Beckman ultracentrifuge
tube and neat trans-encapsidated supernatant was layered on top such
that all air was excluded from the tube before sealing it with Parafilm.
The tube was then left in a horizontal position at 4 uC for 24 h before
being returned to a vertical position. The first 500 ml of the gradient was
removed and discarded, and the remaining contents were centrifuged
at 90 000 g for 24 h at 4 uC in a Beckman SW40 rotor. Fractions (1 ml)
were harvested manually from the top of the gradient and the density of
each was assessed by weighing. Colony-forming assays were performed
by using 500 ml of each fraction and the RNA from a further 200 ml was
harvested by using Total RNA Isolation reagent (ABgene) for analysis
by quantitative RT-PCR (qRT-PCR).
Western blot analysis. Cells were lysed in RIPA buffer [50 mM Tris/
HCl (pH 8.0), 150 mM NaCl, 1 % (v/v) NP-40, 0.5 % (w/v) sodium
deoxycholate, 0.1 % SDS] supplemented with 26 Complete protease
inhibitor cocktail (Roche), and the protein concentration of samples was
determined by using BCA reagent (Pierce). Samples standardized by
protein content (typically 5–10 mg per well) were separated by SDS-PAGE
and transferred to PVDF membrane (Millipore). Membranes were
blocked with 5 % (w/v) low-fat dried milk, 0.1 % Tween 20 (Merck) in
Tris-buffered saline and incubated with sheep anti-NS3 sera or anti-NS5A
(a gift from Dr M. Harris, Institute of Molecular and Cellular Biology,
University of Leeds, UK), murine anti-E2 mAb ALP98 (Clayton et al.,
2002) or murine anti-core mAb 0126 (Biogenesis). Bound antibody was
detected with the appropriate horseradish peroxidase-conjugated sec-
ondary antibody (Sigma) in conjunction with ECL reagent (Amersham
Pharmacia Biotech), and light emissions were captured by film or using a
Versadoc MP4000 imaging system (Bio-Rad).
qRT-PCR. For real-time analysis (qRT-PCR) of RNA after density-
gradient ultracentrifugation, an absolute quantification reaction was
performed. First, a cDNA standard was generated by reverse
transcription of quantified JFH-1 RNA, made previously by in vitro
transcription. Reverse transcription of standard RNA and unknown
sample RNAs was performed by using TaqMan Reverse Transcription
reagents (Applied Biosystems) with random primers. Serially diluted
standard cDNAs and unknown sample cDNAs were analysed in
triplicate by real-time PCR using TaqMan Fast Universal PCR Master
Mix and No ampErase UNG (Applied Biosystems), with final probe
and primer concentrations of 250 and 900 nM, respectively. The
probe sequence was 59-6-FAM-AAAGGCCTTGTGGTACTG-MGB-39
(synthesized by Applied Biosystems), and primer sequences were 59-
TCTGCGGAACCGGTGAGTAC-39 (forward) and 59-GCACTC-
GCAAGCACCCTATC-39 (reverse) (Sigma). Real-time reactions were
amplified under Fast Universal conditions on a 7500 Fast Real-Time
PCR machine and data were analysed by using 7500 Fast System
Software (SDS v. 1.3.1) (Applied Biosystems).
RESULTS
Establishment of donor cell replicon cell lines
Expression of NS2 is known to be essential for effective
virus particle formation (Jones et al., 2007; Pietschmann
et al., 2006; Yi et al., 2007). Whilst there is no absolute
requirement for NS2 to be expressed in cis with either p7 or
NS3 (Jones et al., 2007), it remained possible that the
context within which it was expressed could still influence
virus particle formation. For this reason, two separate
JFH1-based subgenomic replicon constructs were used.
The first was SGR-JFH1(NS3–5B), a bicistronic construct
originally described by Wakita and colleagues (Kato et al.,
2003) that utilizes the HCV IRES and EMCV IRES to
enable expression of neomycin phosphotransferase and the
proteins NS3–NS5B, respectively (Fig. 1a). The second
construct, SGR-JFH1(NS2–5B), was essentially identical to
this construct except that NS2–NS5B was expressed from
the latter cistron. To determine the effectiveness of both
constructs at establishing stable replicon cell lines, T7
polymerase-derived RNA transcripts were transfected into
Huh7 cells and a colony assay was performed. The results
were consistent with the ability of both replicons to
effectively establish replicon-containing cell lines, as their
transfection led to the formation of G418-resistant colonies
not observed in cells transfected with the polymerase
knockout control replicon transcript, although approxi-
mately two-fold more colonies were seen in cells trans-
fected with SGR-JFH1(NS2–5B) compared with those
transfected with SGR-JFH1(NS3–5B) (Fig. 1b). The result-
ing polyclonal cell lines derived from these transfections
were also subjected to Western blot analysis for the
presence of NS3 and NS5A, which confirmed the presence
of the replicons (Fig. 1c).
Provision of structural proteins in trans by using
baculovirus
Having established JFH1-based subgenomic replicon cell
lines, it was necessary to generate an efficient delivery
system for expression of the remaining HCV proteins.
Previous work has demonstrated the effectiveness of a
baculovirus delivery system using a mammalian promoter
for expression of HCV proteins in hepatocyte-derived cell
lines (Fipaldini et al., 1999; McCormick et al., 2002). For
this reason, cDNAs representing part of the JFH1 ORF
encoding the core protein through to p7 and the core
through to NS2 were cloned into a baculovirus transfer
vector that was subsequently used to generate baculovirus
constructs FBM(JFH1)C–P7 and FBM(JFH1)C–NS2
(Fig. 2a). Both baculoviruses promoted effective expression
of core and E2 following their transduction into naı¨ve
Huh7 cells, although there were routinely higher levels of
structural protein expression in cells transduced with
FBM(JFH1)C–P7 (Fig. 2b). Similar results were obtained
in cells harbouring the JFH1-based replicons. Furthermore,
immunoprecipitation of E2 from cell lysates of Huh7 cells
transduced with FBM(JFH1)C–P7 and FBM(JFH1)C–NS2
was found to co-precipitate a comparable amount of E1,
consistent with appropriate E1–E2 heterodimer formation
occurring when using either of these two constructs (data
not shown).
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Trans-encapsidation and transmission of
replicons to naı¨ve Huh7 cells
To test whether trans-encapsidation of subgenomic
replicons and subsequent particle assembly and secretion
can occur when the virus structural proteins are supplied in
trans, cell lines SGR-JFH1(NS2–5B) and SGRJFH1(NS3–
5B) were transduced with the recombinant baculoviruses.
Following incubation for 24 h, the medium from these cells
was assessed for the presence of particles carrying trans-
encapsidated replicon RNA by using a colony-formation
assay (Fig. 3a). Consistent with the need for structural
protein expression for virus particle formation, the
supernatant from mock-transduced SGR-JFH1(NS2–5B)
and SGR-JFH1(NS3–5B) cell lines did not facilitate the
transmission of G418 resistance to naı¨ve Huh7 recipient
cells. Similarly, culture medium from naı¨ve Huh7 donor
cells transduced with FBM(JFH1)C–P7 and FBM(JFH1)C–
NS2 did not confer G418 resistance to the recipient cells,
ruling out any possibility that baculovirus transduction
itself might modulate resistance to the antibiotic. However,
when baculovirus transduction was used to promote HCV
structural protein expression in SGR-JFH1(NS2–5B) and
SGR-JFH1(NS3–5B) cell lines, a small but reproducible
number of G418 colonies was observed. More importantly,
there were significant differences in the number of colonies
seen between these different experimental groups. The
virus-like particles formed from FBM(JFH1)C–P7- or
FBM(JFH1)C–NS2-transduced SGR-JFH1(NS2–5B) cells
demonstrated the most efficient transfer to recipient
Huh7 cells, with the former showing a slightly higher titre,
a finding that may well relate to the overall level of
structural protein expression from these two baculovirus
constructs (Fig. 3a). In contrast, the number of virus-like
particles in the medium of the transduced SGR-JFH1(NS3–
5B) replicon cell line was significantly lower. Moreover, in
the experimental group where the donor SGR-JFH1(NS3–
5B) was transduced with FBM(JFH1)C–P7, only a single
G418-resistant colony was observed from four separate
Fig. 1. Establishment of subgenomic JFH1-based replicon cell
lines. (a) A schematic diagram of the two separate bicistronic
replicon constructs used to generate the replicon-containing cell
lines SGR-JFH1(NS2–5B) and SGR-JFH1(NS3–5B). The neo-
mycin phosphotransferase gene is indicated by neo. (b) Results of
three separate colony-forming assays performed after transfection
of the replicon transcripts into Huh7 cells (mean±SEM). (c)
Western blot analysis was used to confirm expression of NS3
and NS5A in replicon polyclonal cell lines. Lanes: 1, naı¨ve Huh7; 2,
SGR-JFH1(NS2–5B); 3, SGR-JFH1(NS3–5B).
Fig. 2. Characterization of baculovirus constructs for expression
of JFH1 structural proteins. (a) Schematic diagram of the
baculovirus constructs FBM(JFH1)C–P7 and FBM(JFH1)C–
NS2. (b) Western blot analysis was used to examine core and
E2 expression in cell lines that were either mock-transduced (lanes
1, 4 and 7), transduced with FBM(JFH1)C–P7 (lanes 2, 5 and 8)
or transduced with FBM(JFH1)C–NS2 (lanes 3, 6 and 9), using
naı¨ve Huh7 cells (lanes 1–3), SGR-JFH1(NS3–5B) (lanes 4–6)
and SGR-JFH1(NS2–5B) replicon cell lines.
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experiments. This represents a level of transmission
approximately 70-fold lower than that observed when the
same baculovirus construct was used to transduce the SGR-
JFH1(NS2–5B) donor cell line, supporting the proposition
that replicon transmission is occurring through authentic
virus particle formation, as NS2 is known to be required
for efficient virus production and was absent in the former
experimental group. Furthermore, this difference cannot be
accounted for purely by variation in replicative capacities
of the two replicons, because when SGR-JFH1(NS3–5B)
was instead transduced with FBM(JFH1)C–NS2, a five-fold
greater replicon transmission level was observed, despite
the fact that this construct is less effective at facilitating
expression of structural proteins.
In order to rule out the possibility that any mechanism other
than transfer of replicon to recipient cells was occurring in
these experiments, polyclonal cell lines derived from G418-
resistant colonies were also examined for non-structural
protein expression. Western blot analysis demonstrated the
presence of both NS3 and NS5A, confirming that trans-
encapsidation and transfer of the HCV replicon to these
recipient cells had occurred (Fig. 3b).
Optimizing replicon transmission
The above experiments demonstrated that transduction of
the SGR-JFH1(NS2–5B) cell line with FBM(JFH1)C–P7
facilitated the greatest number of replicon transmission
events. However the overall numbers of colonies observed
were low. For this reason, the SGR-JFH1(NS2–5B) cell line
was transduced with different titres of FBM(JFH1)C–P7
and allowed to recover for varying periods of time between
24 and 72 h before the presence of encapsidated replicons
was assessed. Colony-formation results indicated clearly
that the highest titre of baculovirus used, which was the
same as that used in the earlier experiments (46107 p.f.u.
ml21), facilitated the greatest levels of replicon transmis-
sion to naı¨ve cells, although the next lowest titre examined
(26107 p.f.u. ml21) was nearly as effective (Fig. 3c). Lower
levels of replicon transmission were observed when
transducing with a titre of 16107 p.f.u. FBM(JFH1)C–P7
ml21, despite the fact that structural protein expression
could still clearly be detected in the donor cell line by
Western blotting (data not shown). The release of the
trans-encapsidated replicon also varied significantly over
time. Low levels of replicon transmission were detected if
the supernatant from the transduced SGR-JFH1(NS2–5B)
cells was harvested 24 h post-transduction, but this
increased significantly at 48 and 72 h, such that a five- to
Fig. 3. Transmission of replicons from donor cells to recipient
cells by expression of structural proteins. (a) Naı¨ve Huh7 cells,
SGR-JFH1(NS2–5B) and SGR-JFH1(NS3–5B) cell lines were
either mock-transduced or transduced with 4107 p.f.u.
FBM(JFH1)C–P7 or FBM(JFH1)C–NS2 ml”1. The supernatant
was harvested 24 h later, placed on naı¨ve recipient Huh7 cells and
a colony-forming assay was performed. Data represent the
mean±SEM of four separate experiments. (b) G418-resistant
polyclonal cells derived from these transmission experiments were
analysed by Western blotting using anti-NS3 and NS5A antisera.
Experimental groups included cells derived from SGR-JFH1(NS3–
5B) transduced with FBM(JFH1)C–NS2 (lane 2), SGR-
JFH1(NS2–5B) transduced with FBM(JFH1)C-P7 (lane 3) and
SGR-JFH1(NS2–5B) transduced with FBM(JFH1)C–NS2 (lane
4). A cell lysate from mock-transduced cells was used as a
negative control (lane 1). (c) Use of a colony-formation assay to
assess transmission of SGR-JFH1(NS2–5B) to naı¨ve Huh7 cells
after transduction with 1, 2 or 4107 p.f.u. FBM(JFH1)C–P7 ml”1
and harvesting the supernatant at a 24, 48 or 72 h time point.
Results represent single data points from one of three comparable
experiments.
Trans-encapsidation of an HCV replicon
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ten-fold increase was observed. Interestingly, this time
delay in release of trans-encapsidated replicons has also
been reported to be a feature of JFH1 virus particles
generated by using the HCVcc system (Pietschmann et al.,
2006). Although not necessarily linked, there was also an
association between what appeared to be structural
protein-induced cytopathic effect and release of trans-
encapsidated replicons from the donor SGR-JFH1(NS2–
5B) cell line, with extensive cytopathic effect being
observed using 26107 and 46107 p.f.u. FBM(JFH1)C–
P7 ml21 after a 48 h period (data not shown).
Characterization of virus particles
It was clear that expression of structural proteins in the
replicon-containing cells facilitated trans-encapsidation of
the replicon, and that the characteristics of this pheno-
menon paralleled those reported for HCVcc. However, in
order to establish further that trans-encaspidated HCV
replicons represented an appropriate system to study virus
transmission, it was necessary to demonstrate that these
putative virus particles displayed antigenic and physical
properties consistent with those observed for HCVcc.
To confirm that the infection of naı¨ve cells by the replicon-
containing particles was occurring via receptor-mediated
cell entry, the ability of a broadly neutralizing mouse mAb,
AP33 (Owsianka et al., 2005), to block transmission was
assessed. Medium collected from the SGR-JFH1(NS2–5B)
cell line transduced with FBM-JFH1(C–P7) was pre-
incubated for 1 h with AP33 or with DM165 (an irrelevant
IgG1 subtype control) prior to performing a colony-
forming assay. As shown in Table 1, only AP33 was found
to reduce transmission of SGR-JFH1(NS2–5B), thus
confirming that cell entry of replicon-containing particles
was occurring via the interaction between HCV E2 and its
receptor(s), analogous to that observed for HCVcc as well
as retrovirus particles pseudotyped with HCV glycopro-
teins (Owsianka et al., 2005; Tarr et al., 2006).
We next determined the biophysical properties of the
particles present in the medium collected from the SGR-
JFH1(NS2–5B) cell line 72 h post-transduction by isopycnic
centrifugation. Fractions collected from the gradient were
tested for replicon RNA by qRT-PCR and assessed for the
presence of infectious particles by a colony-forming assay
(Fig. 4). Replicon RNA showed marked differences in
distribution, although two distinct peaks of ¡1.03 and
1.13 g ml21 were observed. Interestingly, the most infectious
peak did not correlate with the peaks in HCV RNA level, but
was much broader and distributed between 1.06 and 1.11 g
ml21, similar to the density of infectious HCVcc
(Lindenbach et al., 2005; Yi et al., 2007; Zhong et al.,
2005). One striking feature of these results was the high ratio
of replicon transcripts to infectious particles in the
supernatant; the sum of the data for the gradient analysis
indicated that there were 4.9±1.16105 genome equivalents
per c.f.u. in the unfractioned supernatant (mean±SEM).
A targeted mutation at the end of the core protein
increases replicon transmission
It has been proposed that inefficient particle assembly and
release, characteristic of the JFH1 strain of HCV, are, in part,
related to two amino acids (Phe-172 and Pro-173) near the C
terminus of the core protein and within the E1 signal peptide
region (Delgrange et al., 2007). These residues differ
substantially from Cys and Ser as seen in the core consensus
sequence. To establish whether these amino acids might also
limit trans-encapsidation efficiency, a cDNA representing part
of the JFH1 ORF encoding the core through to p7, but
containing the mutations F172C and P173S, was used to
generate the baculovirus construct FBM(JFH1)C–P7*. A
control construct, FBM(JFH1)E1–P7*, expressing E1–P7 and
which included the E1 signal peptide within the core
sequence, was also generated. Western blot analysis of the
donor SGR-JFH1(NS2–5B) cell line transduced with
FBM(JFH1)C–P7, FBM(JFH1)C–P7* or FBM(JFH1)E1–P7*
demonstrated that comparable levels of E2 expression were
achieved by using all three constructs and confirmed that core
expression was restricted to the first two of these constructs
(Fig. 5a). Transmission of the SGR-JFH1(NS2–5B) replicon
was only observed in experimental groups where baculovirus
constructs expressing all of the structural proteins were used
to transduce the donor cell line, confirming further that the
transmission observed was due to genuine virus particle
formation (Fig. 5b). More importantly, approximately
fourfold more G418-resistant colonies were observed after
Huh7 cells were incubated with supernatant from the
FBM(JFH1)C–P7*-transduced donor cell line compared with
the FBM(JFH1)C–P7-transduced donor cell line. Therefore,
the original core-encoding region of JFH1 is not only
suboptimal for full-length virus production, but also appears
to limit replicon trans-encapsidation.
DISCUSSION
Identification of the JFH1 isolate and its use in the
development of a cell-culture system have greatly facilitated
Table 1. Inhibition of trans-encapsidated replicon infection of
Huh7 cells by mAbs
Medium from the SGR-JFH1(NS2–5B) cell line transduced with
FBM(JFH1)C–P7 was pre-incubated for 1 h with AP33 (a blocking
anti-E2 mAb) or DM165 (an irrelevant IgG1 isotype control) and a
colony-forming assay was performed. Values are shown as c.f.u. ml21
and the percentage of the control (in parentheses), and represent the
mean±SD from triplicate readings generated from two separate
experiments.
[mAb] No antibody AP33 DM165
2 mg ml21 112±8 44±3 (39±3 %) 110±8 (98±7 %)
4 mg ml21 121±13 21±4 (17±3 %) 121±5 (100±4 %)
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the study of virus particle morphogenesis and cell entry.
We now report a further adaptation of the HCVcc system,
namely the packaging of subgenomic replicons into
infectious virus-like particles through provision of struc-
tural proteins in trans. During the preparation of this
manuscript, two other groups also published evidence that
subgenomic replicons could be packaged when structural
proteins were expressed in trans (Ishii et al., 2008;
Steinmann et al., 2008). Our work provides further support
for this finding. The availability of a trans-encapsidation
system for HCV is likely to provide a useful complement to
other systems for studying virus particle formation and
entry.
For trans-encapsidation to be an effective system for
studying HCV biology, transmission of the trans-encapsi-
dated replicon must occur through a process that mimics
that seen for HCVcc. In this study, we found that (i) trans-
encapsidation of the replicon showed a dependence on the
presence of NS2, (ii) trans-expression of the envelope
proteins in the absence of capsid failed to produce
transmissible particles, (iii) the release of virus particles
was maximal approximately 48 h after baculovirus trans-
duction, (iv) an anti-E2 antibody neutralized the trans-
encapsidated particle and (v) these infectious particles had
a peak buoyant density of between 1.06 and 1.11 g ml21.
All of these features are similar to those reported for
replication of JFH1, the full-length construct from which
all constructs used in this study were derived. Many of
these observations also closely parallel those reported in the
two recent HCV trans-encapsidation studies. However, one
novel finding was that expression of NS2 in cis with the
replicon-containing construct greatly enhanced replicon
transmission to naı¨ve recipient cells, compared with its
provision in trans. The lack of a suitable antibody has
prevented us from assessing NS2 expression directly in
replicon-containing and baculovirus-transduced cells.
However, it seems unlikely that NS2 expression levels are
the limiting factor for trans-encapsidation of the replicon.
Instead, as trans-encapsidation of SGR-JFH1(NS2–5B)
correlated with the amount of FBM(JFH1)C–P7 used to
transduce the cell line, it seems more likely that the
structural proteins are the limiting factor for replicon
packaging. Indeed, transduction of SGR-JFH1(NS2–5B)
with FBM(JFH1)C–NS2 resulted in reduced levels of trans-
encapsidation compared with transduction with
FBM(JFH1)C–P7, despite the fact that levels of NS2
Fig. 4. Equilibrium centrifugation of the trans-
encapsidated replicon using an iodixanol
gradient. Cell supernatant from SGR-
JFH1(NS2–5B) cells transduced with 4107
p.f.u. FBM(JFH1)C–P7 ml”1 was harvested
72 h post-transduction and subjected to
equilibrium centrifugation. Fractions from the
gradient were assessed for density (h),
replicon content (by qRT-PCR) (m) and
infectivity by G418 colony assay (g).
Fig. 5. Improved replicon transmission to donor cells using a
modified JFH1 core sequence. (a) Western blotting was used to
assess expression of HCV viral proteins in the SGR-JFH1(NS2–
5B) donor cell line 20 h after mock transduction (lane 1) or
transduction with FBM(JFH1)C–P7 (lane 2), FBM(JFH1)C–P7*
(lane 3) or FBM(JFH1)E1–P7* (lane 4). (b) Supernatants from
SGR-JFH1(NS2–5B) donor cells transduced with the same
constructs were harvested 48 h post-transduction and assessed
for infectivity by a G418 colony assay. Results represent
mean±SD from one of two separate experiments.
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expression would have been greater. Therefore, two
alternative explanations remain that may account for this
apparent preference for expression of NS2 in cis in order to
achieve trans-encapsidation. As SGR-JFH1(NS2–5B) repli-
cates slightly more effectively than SGR-JFH1(NS3–5B), it
is possible that these differences in the trans-encapsidation
assay simply reflect the ability of the replicons to establish
themselves once they have infected naı¨ve Huh7 cells.
Indeed, Steinmann et al. (2008) also observed that trans-
encapsidation efficiency correlated at least partly with
replication efficiency of the HCV transcript being pack-
aged. However, a possible problem with this explanation is
that there is only a two-fold difference in replicative
capacity between SGR-JFH1(NS3–5B) and SGR-
JFH1(NS2–5B) when electroporated into Huh7 cells, but
there is a 10-fold difference in transmission efficiencies of
these two replicons when structural proteins are provided
in trans by FBM(JFH1)C–NS2. The other explanation is
that NS2 expression in cis with other NS proteins in a
replicating HCV transcript positions NS2 within a
particular subcellular compartment to allow it to interact
more effectively with host and viral components necessary
for virus particle formation. This has been shown for
NS5A, which has to be expressed in cis with other NS
proteins in order to undergo appropriate post-translational
modification (Koch & Bartenschlager, 1999; Neddermann
et al., 1999) and gain access to the replication complex
(Appel et al., 2005). Interactions between NS5A and the
core protein are then thought to facilitate interactions
between the replication complex and lipid droplets where
particle assembly occurs (Appel et al., 2008; Masaki et al.,
2008; Miyanari et al., 2007). However, unlike the situation
for NS5A, if this latter model is correct, then there is no
obligatory requirement for NS2 to be expressed in cis,
simply a preference for it. Further work is needed to
establish exactly how trans-encapsidation might be affected
by the context in which NS2 is expressed.
Trans-encapsidation in this study was achieved via
transduction with baculoviruses expressing the HCV
structural proteins, rather than through the generation
of a packaging cell line or co-transfection with a helper
virus as performed by others (Ishii et al., 2008; Steinmann
et al., 2008). Unlike the use of helper virus, the
baculovirus system also allows production of trans-
encapsidated material that is free from other HCV
replication-competent RNAs, thus simplifying data inter-
pretation. This, coupled with the fact that baculovirus
constructs expressing HCV structural proteins can be
generated much more rapidly than stable cell lines, means
that, for locations where an appropriate biocontainment
facility for HCVcc work is unavailable, our system is likely
to be more tractable for use in reverse-genetics studies of
virus particle formation and entry. Indeed, we now have
preliminary data showing that trans-encapsidation of
transient luciferase-expressing replicons occurs after
transduction with baculovirus expressing structural pro-
teins (data not shown). Thus, the baculovirus-based
system can achieve trans-encapsidation of subgenomic
replicons without the use of helper virus or the need to
establish either a stable packaging cell line or a replicon
cell line. Furthermore, baculoviruses expressing structural
proteins derived from diverse HCV genotypes and
subtypes would allow generation of pseudotyped VLPs,
thus facilitating studies on the effects of genetic variation
on virus particle assembly and entry. We have not tested
whether expression of structural proteins by transient
transfection of plasmid might also allow trans-encapsida-
tion of replicons. However, given the typically low
efficiency with which plasmid transfection occurs into
Huh7 cells, coupled with our observation that high levels
of structural protein expression are necessary to achieve
efficient packaging, it is likely that levels of trans-
encapsidation would be much lower and possibly below
a detectable threshold.
The maximum level of replicon trans-encapsidation that
we observed when using the original JFH1 structural
coding region was approximately 102 c.f.u. ml21, although
there was some variability between experiments. This
maximum level is comparable with the levels of trans-
encapsidation observed by Ishii et al. (2008), who also used
JFH1-based constructs, but is in marked contrast to the
very high level of replicon transcripts released into the
supernatant, suggesting that most of these transcripts are
released either as extracellular membrane-associated RNAs
or as defective virus particles, a feature of HCVcc and even
more so of the HCV trans-encapsidation systems.
Steinmann et al. (2008) found that the use of structural
proteins from the J6 genotype 2b infectious clones,
combined with the use of a chimaeric NS2 sequence,
improved the production of infectious particles by several
log orders of magnitude. We have also found that titres of
infectious particles can be increased by changing the
structural ORF, although in our study this was achieved by
targeted mutations within the core-encoding region rather
than by use of a chimaeric construct. We anticipate that
further modifications, perhaps comparable to those used
by Steinmann et al. (2008), could be used to improve
baculovirus-based trans-encapsidation further.
In conclusion, we have developed a robust system that
permits experimental separation of HCV replication and
packaging functions, and which can be used without the
need for stringent biocontainment. This system comple-
ments the existing HCVcc and retrovirus-based surrogate
HCV pseudoparticle systems as a valuable tool for the
study of HCV virus particle assembly and entry.
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